6月24日，省委宣传部、省政府新闻办公室举办"持续深化'三个年'活动、聚力打好重点领域攻坚硬 仗"系列新闻发布会。 省卫生健康委副主任赵岚介绍，今年以来，全省开展"改善就医感受 提升患者体验"主题活动，持 续提高医疗服务质量，着力解决人民群众看病就医急难愁盼问题。 持续拓展医疗服务供给 陕西创新门诊服务模式，指导二级以上公立医疗机构积极开设体重管理、心理、睡眠、青少年近 视、药学、疼痛等新型门诊，有效覆盖健康管理服务领域。截至目前，全省199家医疗机构开设体重管 理门诊，154家医疗机构开设心理门诊和睡眠门诊。 推动二级以上公立医疗机构、乡镇卫生院和社区卫生服务中心开设节假日门诊，鼓励提供延时门诊 服务，解决上班族、学生族就医时间冲突问题。 落实基层医疗服务便民惠民措施。截至目前，全省95%以上的基层医疗卫生机构可以提供高血压、 糖尿病长处方服务。推动家庭医生签约服务与基本公卫融合，全省重点人群签约率超80%，65岁以上老 年人及高血压、2型糖尿病、慢阻肺病、严重精神障碍、肺结核等5类重点慢病规范管理率达到国标。 全省深化"方便看中医、放心用中药"惠民活动，分层次建设国家级、省级和市县级中医优势特色专 科。截 ...

Core Viewpoint - WuXi AppTec, a leading CRO company, has completed a share repurchase of approximately 1 billion yuan, marking its second repurchase in 2025, with a total of 40 billion yuan repurchased since 2024 [1][2][3] Group 1: Share Repurchase - The company has completed its second share repurchase in 2025, buying back 15.7754 million shares at an average price of 63.39 yuan per share, totaling around 1 billion yuan [2] - Since 2024, WuXi AppTec has conducted five "cancellation-style" repurchases, with four completed, amounting to a total of 40 billion yuan [1][3] - The purpose of these repurchases is to reduce the company's registered capital and enhance shareholder value [2][3] Group 2: Financial Performance - Since its IPO in 2018, WuXi AppTec has achieved a cumulative net profit of 43.716 billion yuan and a total cash dividend of 13.93 billion yuan, with a dividend payout ratio of 31.87% [1][3] - In Q1 2025, the company reported a revenue of 9.65 billion yuan, a year-on-year increase of approximately 21%, and a net profit of 3.673 billion yuan, reflecting a growth of 89.06% [4][5] - The company’s order backlog as of March 2025 stands at 52.33 billion yuan, a year-on-year increase of 47.1% [6]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-042 无锡药明康德新药开发股份有限公司 关于 2025 年第一次以集中竞价交易方式回购 A 股股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：无锡药明康德新药开发股份有限公司（以下简称"公司"） 本次回购资金总额为人民币 10 亿元。 一、 回购方案的审议及实施程序 别股东会议和 2025 年第一次 H 股类别股东会议审议通过了《关于给予董事会回购 公司 A 股和/或 H 股股份一般性授权的议案》，授权董事会按照所适用的法律法规 和/或规定行使公司全部权力，在有关期间回购公司 A 股和/或 H 股总面值不超过 该议案经股东大会、A 股及 H 股类别股东会议分别审议通过之日公司已发行 A 股 和/或 H 股股份数量的 10%（以下简称"A 股回购一般性授权"）。如果公司前述 A 股回购一般性授权的授权期限届满前未完成本次回购股份，在本次回购股份数量 上限不超过公司股东大会及类别股东会批准的下一年度 A 股 ...

Core Viewpoint - The National Healthcare Security Administration has issued a notice to strengthen the management of designated medical institutions under the medical insurance system, emphasizing strict supervision of medical insurance funds to ensure the quality of healthcare services and protect patients' rights [1]. Group 1: Regulations for Designated Medical Institutions - Medical institutions applying to become designated under the insurance scheme must use drug and consumable traceability codes, ensuring comprehensive collection and payment based on these codes [2]. - Designated public medical institutions must adhere to government-guided pricing for basic medical services, while non-public institutions must commit to the same pricing standards and principles of fairness and quality [2]. - A six-month policy guidance period is established for newly designated institutions to comply with insurance management and payment policies, with penalties for violations during this period [2]. Group 2: Patient Rights and Service Standards - It is strictly prohibited to force patients to purchase drugs or consumables outside the institution or to discharge them prematurely based on insurance policies [5]. - Designated public medical institutions are required to procure drugs and consumables through provincial centralized procurement platforms, ensuring compliance with traceability codes [5]. - Institutions must provide necessary prescription services for drugs that are temporarily unavailable, ensuring smooth electronic prescription processes [5]. Group 3: Monitoring and Exit Mechanisms - The notice mandates enhanced monitoring of hospitalization behaviors for vulnerable groups, including those with chronic or special diseases, to ensure timely provision of insurance services [8]. - A robust exit mechanism for designated medical institutions is required, with strict penalties for fraudulent activities or failure to comply with documentation requirements [8]. - The management of healthcare professionals involved in insurance fund usage will be strengthened through a point-based system, leading to potential penalties for those accumulating excessive points [8].

Group 1 - AMN Healthcare Services (AMN) closed at $21.18, with a 2% gain over the past four weeks, and a mean price target of $27.39 suggests a 29.3% upside potential [1] - The average price targets from analysts range from $24.00 to $33.00, indicating a potential increase of 13.3% to 55.8%, with a standard deviation of $3.88 reflecting the variability of estimates [2] - Analysts show strong agreement that AMN will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for AMN's current year earnings has increased by 6.3% over the past month, with no negative revisions [12] - AMN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [14]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongce Medical, which closed at 40.74 yuan with a PE ratio of 35.58 times, and a total market capitalization of 18.223 billion yuan [1][2] - The average PE ratio for the medical services industry is 39.95 times, with a median of 41.77 times, positioning Tongce Medical at the 26th rank within the industry [1][2] - As of the first quarter of 2025, 21 institutions hold shares in Tongce Medical, including 18 funds, with a total holding of 209.5898 million shares valued at 9.488 billion yuan [1] Group 2 - Tongce Medical's main business focuses on providing oral medical services and research, with key products including medical services, product sales, construction engineering, and comprehensive service fees [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 745 million yuan, representing a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up by 6.22%, with a gross profit margin of 44.21% [1]

新京报讯（记者陈琳）在生命的终章，安宁疗护是守护尊严与温度的最后灯塔。近日，北京市地方标准 《医疗机构安宁疗护服务规范》（以下简称《规范》）正式实施，为全国医疗机构安宁疗护服务标准化 建设树起新标杆。 《规范》从"硬门槛"到"软服务"完善全链条标准规范。在机构资质方面，明确要求临终关怀执业登记， 确保服务专业性；人才队伍实行"核心+补充"模式，以执业医护为核心，配备康复医师、精神科医师、 医务社工等专业力量，打造多学科服务矩阵。硬件设施方面，从5平方米/床的住院空间到隔帘隐私保 护，从基础护理设备到智能监测系统，全方位保障患者舒适体验。服务流程贯穿门诊咨询、入院评估、 个性化方案制定、症状综合干预全流程，创新性融合中西医诊疗与自然医学疗法，实现"身体-心理-精 神"的三维照护。 《规范》突出三大亮点，在全国首次将医务社工纳入核心服务团队，构建"医-护-社"协同模式，开创多 学科联动先河；强调"患者及家属共同决策"机制，让生命末期的选择权与知情权回归家庭；突破性融合 中医药适宜技术、冥想疗法等特色手段，形成中西医结合的"北京特色"安宁疗护方案。这些创新举措为 全国安宁疗护标准化建设提供了可复制、可推广的实践样本 ...

Group 1 - The core viewpoint of the article is the strategic collaboration between Aixin Life Insurance and Century Kangrui Medical Group to explore innovative models of medical insurance and health management, focusing on chronic disease management and patient care [1][10]. Group 2 - Century Kangrui, established in 2014, has developed a comprehensive medical service chain that includes emergency rescue, cancer treatment, and rehabilitation care, operating 11 medical institutions, which aligns well with Aixin Life's strategy of integrating insurance and medical services [3]. - Aixin Life is focusing on innovative insurance products for patients with chronic diseases and those with positive health indicators, aiming to break traditional underwriting limitations and provide valuable health management solutions [5][10]. Group 3 - The collaboration will leverage the overlapping customer bases of both companies and will focus on developing "insurance + health management" combination products for chronic diseases such as diabetes and hypertension, enhancing the integration of medical services and insurance protection [7]. Group 4 - Following the agreement, both companies will establish a special task force to facilitate practical cooperation in product development, customer service, and health management, aiming to accelerate the implementation of innovative projects [8]. Group 5 - This partnership marks a significant step for Aixin Life in deepening its "insurance + medical care" strategy, enhancing its service capabilities in chronic disease management and providing a valuable model for the industry in integrating medical and insurance services [10].

Core Viewpoint - Baize Medical Group Limited has successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 560 million through the issuance of 133 million shares at a price of HKD 4.22 per share [1][3]. Group 1: Listing Details - On its first trading day, Baize Medical opened at HKD 5.25 per share, a 24.41% increase from the IPO price, and closed at HKD 6.00 per share, representing a 42.18% increase [3]. - The public offering was oversubscribed by 25.92 times, while the international offering was subscribed at 0.98 times [3]. - A cornerstone investor, Harvest Oriental, invested USD 19 million in the company's shares [3]. Group 2: Company Overview - Established in July 2017, Baize Medical primarily engages in investment and provision of medical services, focusing on oncology [5]. - The company operates and manages eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces, including six for-profit and two non-profit hospitals [5]. Group 3: Financial Performance - Revenue for Baize Medical was approximately RMB 802.65 million in 2022, RMB 1.07 billion in 2023, and is projected to reach RMB 1.19 billion in 2024 [6]. - Adjusted net profit was reported as RMB -75.34 million in 2022, RMB -9.62 million in 2023, and is expected to be RMB 12.50 million in 2024 [7]. - Adjusted EBITDA figures were RMB 35.14 million in 2022, RMB 107.51 million in 2023, and projected at RMB 119.55 million in 2024 [7].

作者 | 第一财经 陈玺宇 当地时间20日，英国议会下院以314票赞成、291票反对的结果，艰难通过了"重症晚期成年人（生命 终结）法案"（Terminally Ill Adults (End of Life) Bill）三读。 这项由工党议员金·利德比特（Kim Leadbeater）提出的法案，允许处于重症晚期且预期寿命在6个月 以内的、心智健全的成年人在英格兰和威尔士通过医疗手段结束自己的生命。 按照英国立法程序，法案接下来将提交英国议会上院审议，预计仍需数月时间。鉴于上院只能提出修 正或推迟，无法否决下院已三读通过的法案，外界普遍预计该法案最终或将获得通过。英国现任首 相、工党党魁斯塔默（Keir Starmer）在此次表决中投下赞成票。 投票前，议员们展开了长时间的辩论和激烈对峙。支持者以"几十年来最重要的社会改革"来形容此次 立法进程，反对者则警告，法案蕴含着巨大的社会风险。投票当天，来自英国各地、手持标语和横幅 的民众聚集在伦敦市中心的议会大厦门外。 据环球时报，在英格兰和威尔士地区，安乐死仍属于非法行为，协助他人死亡者最高面临14年监 禁。过去20年，已有超过3900名英国公民辗转前往瑞士机构 ...